- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2030
Diabetic Peripheral Neuropathy – Disease Overview
Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.
As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies.
Diabetic Peripheral Neuropathy Epidemiology
DelveInsight’s estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
Visit to know more about the report: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market
Diabetic Peripheral Neuropathy Market: Treatment and Emerging Therapies
The rising global burden of diabetes is spurring an increase in the prevalence of diabetic neuropathy and neuropathic pain. At present, there are no FDA-approved pathogenetic therapies for DPN and the efficacy of treatments for painful DPN is limited.
The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.
Treatments currently approved by both FDA and EMA for pain associated with DPN include—pregabalin, duloxetine, and extended-release tapentadol and capsaicin 8% patch. However, no treatments have been approved for the prevention or reversal of DPN.
According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.
Request for sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market
Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies.
The key pharma players working in Diabetic Peripheral Neuropathy Market are:
3. WinSanTor, Inc
4. Regenacy Pharmacuticals
5. Ichnos Science
7. Grünenthal GmbH
8. Glenmark Pharmaceuticals
And many others
Diabetic Peripheral Neuropathy Report Insights
- Patient Population of Diabetic Peripheral Neuropathy
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Table of Contents
1. Key Insights
2. Executive summary
3. Diabetic Peripheral Neuropathy Market Overview at a Glance
4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology
5. Diabetic Peripheral Neuropathy Disease Background and Overview
6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population
7. Diabetic Peripheral Neuropathy Treatment and Management
8. Diabetic Peripheral Neuropathy Unmet needs
9. Diabetic Peripheral Neuropathy Marketed Drugs
10. Diabetic Peripheral Neuropathy Emerging drugs
11. Diabetic Peripheral Neuropathy Market Size
12. Diabetic Peripheral Neuropathy Reimbursement policies
13. Diabetic Peripheral Neuropathy Market Drivers
14. Diabetic Peripheral Neuropathy Market Barriers
15. SWOT Analysis
16. KOL Views
17. Diabetic Peripheral Neuropathy Case Report
18. A Case Report of Diabetic Peripheral Neuropathy
21. Diabetic Peripheral Neuropathy Report Methodology
22. DelveInsight Capabilities
24. About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States